General Information

Metronidazole is a nitroimidazole antibiotic medication used particularly for anaerobic bacteria and protozoa.

Metronidazole 1.3% Vaginal Gel is specifically indicated for the treatment of bacterial vaginosis in non-pregnant women.

Metronidazole 1.3% is supplied as a vaginal gel for topical administration. Metronidazole vaginal gel 1.3% should be administered once intravaginally at bedtime.

Clinical Results

FDA Approval
The FDA approval of Metronidazole vaginal gel 1.3% was based on a phase III randomized, double-blind, placebo-controlled, multicenter clinical trial. Metronidazole 1.3% was compared to MetroGel-Vagina (metronidazole vaginal gel 0.75%). Results showed that the higher concentration Metronidazole 1.3% was well tolerated and efficacious.

Side Effects

Adverse effects associated with the use of Metronidazole vaginal gel 1.3% may include, but are not limited to, the following:

• vulvovaginal candidiasis
• headache
• vulvovaginal pruritus
• nausea
• diarrhea
• dysmenorrhea

Mechanism of Action

Metronidazole is a nitroimidazole antibiotic medication used particularly for anaerobic bacteria and protozoa.

Additional Information

For additional information regarding Metronidazole 1.3% Vaginal Gel or bacterial vaginosis, please visit the Actavis web page.